Quinapril detailed information

Quinapril detailed information

Clinical data
Pregnancy category	D
ATC code	C09AA06 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding	97%
Elimination half-life	2 hours
Identifiers
IUPAC name (3S)-2-[(2S)-2-[[(1S)-1-ethoxycarbonyl-3-phenyl- propyl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline- 3-carboxylic acid
CAS Number	85441-61-8
PubChem CID	54892
DrugBank	APRD00523
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C25H30N2O5
Molar mass	438.516 g/mol

WikiDoc Resources for Quinapril detailed information
Articles
Most recent articles on Quinapril detailed information Most cited articles on Quinapril detailed information Review articles on Quinapril detailed information Articles on Quinapril detailed information in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Quinapril detailed information Images of Quinapril detailed information Photos of Quinapril detailed information Podcasts & MP3s on Quinapril detailed information Videos on Quinapril detailed information
Evidence Based Medicine
Cochrane Collaboration on Quinapril detailed information Bandolier on Quinapril detailed information TRIP on Quinapril detailed information
Clinical Trials
Ongoing Trials on Quinapril detailed information at Clinical Trials.gov Trial results on Quinapril detailed information Clinical Trials on Quinapril detailed information at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Quinapril detailed information NICE Guidance on Quinapril detailed information NHS PRODIGY Guidance FDA on Quinapril detailed information CDC on Quinapril detailed information
Books
Books on Quinapril detailed information
News
Quinapril detailed information in the news Be alerted to news on Quinapril detailed information News trends on Quinapril detailed information
Commentary
Blogs on Quinapril detailed information
Definitions
Definitions of Quinapril detailed information
Patient Resources / Community
Patient resources on Quinapril detailed information Discussion groups on Quinapril detailed information Patient Handouts on Quinapril detailed information Directions to Hospitals Treating Quinapril detailed information Risk calculators and risk factors for Quinapril detailed information
Healthcare Provider Resources
Symptoms of Quinapril detailed information Causes & Risk Factors for Quinapril detailed information Diagnostic studies for Quinapril detailed information Treatment of Quinapril detailed information
Continuing Medical Education (CME)
CME Programs on Quinapril detailed information
International
Quinapril detailed information en Espanol Quinapril detailed information en Francais
Business
Quinapril detailed information in the Marketplace Patents on Quinapril detailed information
Experimental / Informatics
List of terms related to Quinapril detailed information

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

For patient information, click here

Quinapril (marketed under the brand name Accupril by Pfizer) is an angiotensin-converting enzyme inhibitor (ACE inhibitor) used in the treatment of hypertension and congestive heart failure.

Pharmacology

Quinapril is a prodrug. It is converted to its active metabolite, quinaprilat, in the liver.

Mechanism of action

Main article: ACE inhibitor

See also: Angiotensin and renin-angiotensin system

Quinapril inhibits angiotensin converting enzyme, an enzyme which catalyses the formation of angiotensin II from its precursor, angiotensin I. Angiotensin II is a powerful vasoconstrictor and increases blood pressure through a variety of mechanisms. Due to reduced angiotensin production, plasma concentrations of aldosterone are also reduced, resulting in increased excretion of sodium in the urine and increased concentrations of potassium in the blood.

Indications

Quinapril is indicated for the treatment of high blood pressure (hypertension) and as adjunctive therapy in the management of heart failure. It may be used for the treatment of hypertension by itself or in combination with thiazide diuretics, and with diuretics and digoxin for heart failure.

Contraindications

Pregnancy

Impaired renal and liver function

Patients with a history of angioedema related to previous treatment with an ACE inhibitor.

Hypersensitive to Quinapril

Side effects

Side effects of quinapril include dizziness, cough, vomiting, upset stomach and fatigue.

External links

• Quinapril FAQ
• Accupril Site

Template:ACE inhibitors hu:Quinapril

Template:WikiDoc Sources